Phase 2 Start

CMPX: Phase 2 Start: A Phase 2, Open-Label Study of CTX-471 in Patients With NCAM Positive Tumors

Name: Phase 2 Start: A Phase 2, Open-Label Study of CTX-471 in Patients With NCAM Positive Tumors
Start: 2026-09-01
End: 2026-09-01

September 1, 2026 · ctx-471. BioSniper AI can trace the company-impact path without requiring you to write the research question.

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Traceable citations · Unknowns marked

Phase 2 Start~month

Phase 2 Start: A Phase 2, Open-Label Study of CTX-471 in Patients With NCAM Positive Tumors

September 1, 2026

Company: Compass Therapeutics, Inc. (CMPX)
Drug: ctx-471
Indication: Neuroendocrine Tumors; Neuroendocrine Carcinomas; Neuroendocrine Neoplasm